Skip To Main Content
A. Bardelli on Muck Rack

A. Bardelli

As seen in: Nature, Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with A.

Contact A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors - British Journal of Cancer

|
By A. Bardelli
| Nature Verified
Abstract Colorectal cancer (CRC) remains one of the major causes of cancer death worldwide. Chemotherapy continues to serve as the primary treatment modality, while immunotherapy is largely ineffective for the majority of CRC patients. Seminal discoveries have emphasized that modifying DNA damage response (DDR) mechanisms confers both cell-autonomous and immune-related vulnerabilities across various cancers.
Open in Who Shared Issue with article?

Consensus on precision medicine for metastatic cancers: a report from the MAP conference

|
By C. Swanton, J. -C. Soria, Gustave Roussy, A. Bardelli, A. Biankin
| Annals of Oncology Verified
Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The first MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. Sixteen consensus items were covered.
Open in Who Shared Issue with article?

Consensus on precision medicine for metastatic cancers: A report from the MAP conference

|
By Gustave Roussy, C. Swanton, J-C. Soria, A. Bardelli, A. Biankin
| Annals of Oncology Verified
Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The 1st MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. 16 consensus items were covered.
Open in Who Shared Issue with article?
See all 3 articles